Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for Progressive MS
NCT03778333Phase 1Completed
- Sponsor
- Karolinska Institutet
- Start
- Dec 2012
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous mesenchymal stem cells in multiple sclerosis (MS), sponsored by Karolinska Institutet. Primary endpoints: Number of participants with an adverse event related to the treatment at 48 weeks and Cumulative number of MRI T2 lesions at 48 weeks. Started Dec 2012; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03778333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778333.